Tenax Therapeutics reported a wider net loss for its fiscal second quarter ended June 30, 2026, with the loss increasing 64% to $17.80 million from $10.85 million a year earlier. Diluted loss per share rose to $0.35 from $0.27 in the prior-year quarter. Cash and cash equivalents stood at $118 million as of June 30, 2026, and following $13.4 million in gross proceeds from warrant exercises during the quarter, the company expects its cash runway to extend through the second quarter of 2028. Tenax anticipates topline data in August 2026 from the Phase 3 LEVEL trial of TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction.
Tenax Therapeutics IncWider Q2 loss and increased loss per share reported.